Loading stock data…
DiaMedica Therapeutics Inc (DMAC)
$6.54-0.21 (-3.11%)
Market ClosedLast close Sep 8
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DiaMedica Therapeutics Inc. in the Healthcare sector is trading at $6.54 with a market capitalization of $293M. Wall Street consensus targets $15.50 (4 analysts), implying a +137.0% move over the next 12 months. The stock is currently 37% below its 52-week high of $10.42, remaining 9.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +137.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.48M↓ | -$9.21M↓ | -$9.03M↓ | -$8.01M↑ | -$8.14M |
| Net Income | -$10.04M↓ | -$8.74M↓ | -$8.62M↓ | -$7.70M↑ | -$7.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$292.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-74.31%
Volume
Today's trading volume
118,751
Recent News
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete.
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...
DMAC reports statistically significant blood pressure reductions in late-onset preeclampsia, progresses FGR study, and maintains cash runway through 2027 despite increased R&D spending.
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby summary of DiaMedica Therapeutics Inc.'s Q2 2026 earnings call